The Clinical Observation Of Qixing Dan Treating Chronic Skin Ulcer

Objectives:Comparative observeing therapeutic effects of Qixing Dan and Recombinant Bovine Basic Fibroblast Growth Factor Gelatin (Beifuxin) treating chronic skin ulcer, to provide certain objective cases meditation guidelines for chronic skin ulcer in clinical local application.Methods:Divided patients who conformed to diagnostic and inclusive criteria into 2 groups randomly, that specifically 30 cases in Qixing Dan group and 30 cases in Beifuxin group. Subsequently assessed the symptoms and signs of type Ⅲ and type Ⅳ ulcer surfaces recorded before and after treatment by scores, observed color-altering time, granulation-generating time and relevant adverse reactions after dressing respectively. Taked account of whether recrudesce appearing or not during the one-month follow-up phase after a course. Compared the clinical efficacy and start time of granulation generating between two groups, meanwhile, made inter and intra-group comparisons of the clinical efficacy pointed at two types of ulcer.Results:The total effective rate was was 93.3% in Qixing Dan group, and respectively 100%,84.6%, that 63.3% in Beifuxin group, respective 87.2%,27.2% in type Ⅲ and type IV cases in the two types.. P<0.05 as comparing total effective rates in both groups, leading to the result that Qixing Dan performs more powerfully on the treatment than Beifuxin. As to the therapeutic roles in cases of type Ⅲ ulcer played by both treated groups, were more obvious than those of type Ⅳ ulcer. The clinical efficacy that two medicines possessed on type Ⅲ ulcer had a obvious statistical discrepancy, with a statistical analytic result that P<0.05. At the same time, the clinical efficacy that two medicines possessed on type Ⅳ ulcer had a obvious statistical discrepancy, with a statistical analytic result that P<0.05. There exists significant difference in color-altering time of ulcer surfaces and granulation-generating time between two groups, from which we can conclude that Qixing group exerted more significantly than Beifuxin group.Conclusions:Qixing Dan tends to be worthy of clinical application for promoting the granulation generation on ulcer surfaces, and superior to Beifuxin in curing type Ⅲ and type Ⅳ ulcers. Both these medicine have better clinical outcomes aimed at type Ⅳ ulcer compared to those in type Ⅲ ulcer.